In this study, we discovered that in patient-derived, high-stage NB cells that express wild-type TP53, FOXO3 interacts with TP53, which prevents the binding of FOXO3 to the BIM-promoter and FOXO3-induced cell death. The gene discussed is BCL2L11; the disease is neuroblastoma.